A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001
Phase of Trial: Phase IV
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Brincidofovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Chimerix
- 09 May 2019 Status changed from recruiting to discontinued, according to a Chimerix media release.
- 31 Jul 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2025.
- 25 Jun 2014 New trial record